FSH may mediate the association between HbA1c and bone turnover markers in postmenopausal women with type 2 diabetes.

Abstract

Recent studies in postmenopausal women have found associations of follicle-stimulating hormone (FSH) levels with both glucose metabolism and bone turnover. The objective of the study was to investigate whether FSH may contribute to suppressed bone turnover markers (BTMs) in postmenopausal women with type 2 diabetes (T2D). 888 postmenopausal women with T2D, 352 nondiabetes (prediabetes plus normoglycemia) were included from the METAL study. HbA1c, sex hormones, 25-hydroxy vitamin D (25(OH)D), serum procollagen type I N-terminal propeptide (P1NP), and β-C-terminal telopeptide (β-CTX) were measured. P1NP and β-CTX decreased in postmenopausal T2D women compared with nondiabetes controls (both p < 0.001). The major factors responsible for the changes in P1NP were HbA1c (β = -0.050, p < 0.001), 25(OH)D (β = -0.003, p = 0.006), FSH (β = 0.001, p = 0.044) and metformin (β = -0.109, p < 0.001), for β-CTX were HbA1c (β = -0.049, p < 0.001), body mass index (BMI) (β = -0.011, p = 0.005), 25(OH)D (β = -0.003, p = 0.003), FSH (β = 0.002, p = 0.022) and metformin (β = -0.091, p = 0.001) in postmenopausal T2D women based on multivariate regression analysis. With the increase in HbA1c, FSH decreased significantly (p for trend < 0.001). Mediation analysis demonstrated that FSH partly mediated the suppression of LnP1NP and Lnβ-CTX by HbA1c (β = -0.009 and -0.010, respectively), and Lnβ-CTX by BMI (β = -0.015) when multiple confounders were considered (all p < 0.05). HbA1c was the crucial determinant contributing to the suppression of BTMs. FSH might play a novel mediation role in BTM suppression due to HbA1c or BMI.